About

Bing Liu is a Clinical Associate Professor of General Dentistry at the Henry M. Goldman School of Dental Medicine. He earned his DMD and DScD (Oral Biology) from the Henry M. Goldman School of Dental Medicine in 2003 and 1999, respectively, and holds a BDS from Beijing Medical University in China, obtained in 1992. His academic and professional focus is within the departments of General Dentistry and Operative Dentistry, specifically in the divisions of Predoctoral Removable Prosthodontics. As a faculty member, he contributes to the education and training of dental students, emphasizing comprehensive dental care and clinical excellence.

Research topics

• Medicine
• Biology
• Internal medicine
• Endocrinology
• Neuroscience
• Psychiatry
• Psychology
• Oncology
• Biochemistry

Selected publications

• Tirzepatide Once Weekly for the Treatment of Obesity

  New England Journal of Medicine · 2022 · 2999 citations

  • Medicine
  • Endocrinology
  • Internal medicine

  BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).

  DOI

• Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

  New England Journal of Medicine · 2021 · 1787 citations

  • Medicine
  • Internal medicine
  • Endocrinology

  BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).

  DOI

• A neuroimaging biomarker for striatal dysfunction in schizophrenia

  Nature Medicine · 2020 · 253 citations

  Senior authorCorresponding
  • Psychology
  • Neuroscience
  • Medicine
  DOI

• VTA Glutamatergic Neurons Mediate Innate Defensive Behaviors

  Neuron · 2020 · 136 citations

  • Neuroscience
  • Biology
  • Biochemistry
  DOI

Recent grants

• III: Medium: Collaborative Research: Collective Opinion Fraud Detection: Identifying and Integrating Cues from Language, Behavior, and Networks

  NSF · $300k · 2014–2018

Frequent coauthors

• Tianzi Jiang

  Zhejiang Lab

  595 shared

• Yong Liu

  Beijing University of Posts and Telecommunications

  306 shared

• Lingzhong Fan

  Chinese Academy of Sciences

  124 shared

• Chunshui Yu

  University of Toronto

  115 shared

• Dai Zhang

  Peking University Sixth Hospital

  111 shared

• Ming Song

  Institute of Automation

  93 shared

• Ang Li

  Shanghai Advanced Research Institute

  92 shared

• Haichang Wang

  China Academy of Transportation Sciences

  91 shared

Education

• Other

  Henry M. Goldman School of Dental Medicine

  2003

• Other, Oral Biology

  Henry M. Goldman School of Dental Medicine

  1999

• Other

  Beijing Medical University (China)

  1992

Similar researchers at Boston University

• Alexa S. Beiserh-188
• David Boash-156
• Benjamin Sovacoolh-143
• Kathryn L. Lunettah-132
• Ranga Mynenih-130